Eloxx Pharmaceuticals Inc represents values of innovation, dedication, and patient-centricity. The company's corporate philosophy revolves around addressing the unmet medical needs of patients with genetic diseases caused by nonsense mutations. Eloxx Pharmaceuticals is committed to developing transformative therapies through its proprietary RNA-targeted technology platform. By harnessing the potential of genetic medicine, Eloxx aims to provide hope and improved quality of life for patients worldwide. This dedication to advancing treatments and making a positive impact underscores Eloxx Pharmaceuticals' commitment to excellence and driving meaningful change in healthcare.

Eloxx Pharmaceuticals Inc is primarily present in the United States.

Eloxx Pharmaceuticals Inc has achieved several significant milestones. The company successfully completed a Phase 1 clinical trial for its lead investigational drug ELX-02, demonstrating its safety and tolerability. Eloxx also received Fast Track designation from the U.S. FDA for the treatment of cystic fibrosis, highlighting the potential of its innovative therapies. Moreover, Eloxx secured a collaboration agreement with Zhejiang University to advance translational medicine studies in rare and ultra-rare genetic diseases. Additionally, the company expanded its pipeline by advancing multiple programs targeting genetic diseases caused by nonsense mutations. Through these achievements, Eloxx Pharmaceuticals Inc has demonstrated its commitment to developing novel treatments for patients with rare and severe genetic diseases.

Eloxx Pharmaceuticals Inc is a renowned biopharmaceutical company specializing in the development of novel therapeutic compounds for genetic diseases. Founded in 2013, Eloxx has rapidly gained recognition for its innovative approach to treating rare and ultra-rare diseases caused by nonsense mutations. With a strong focus on advancing translational science, the company aims to address critical unmet needs in the medical community. Eloxx's dedication to research and development has resulted in the discovery of potential therapies, such as its lead product candidate ELX-02, which demonstrates promising preclinical and clinical data. As a frontrunner in the field, Eloxx Pharmaceuticals Inc continues to strive towards improving the lives of patients with genetic diseases.

The main competitors of Eloxx Pharmaceuticals Inc in the market include other pharmaceutical companies involved in the development and commercialization of novel therapies. Some notable competitors include Vertex Pharmaceuticals, Translate Bio, and Ionis Pharmaceuticals. These companies are also focused on developing innovative treatments for genetic diseases and potentially compete with Eloxx Pharmaceuticals Inc in the same therapeutic areas.

Eloxx Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

The business model of Eloxx Pharmaceuticals Inc focuses on the development and commercialization of novel medicines for the treatment of rare and ultra-rare genetic diseases caused by nonsense mutations. Eloxx Pharmaceuticals utilizes its proprietary RNA modulation platform to target and restore the production of functional proteins. By addressing the underlying genetic cause of these diseases, the company aims to provide potential therapies that could significantly improve patients' lives. Eloxx Pharmaceuticals is dedicated to advancing innovative therapies and serving the unmet medical needs of individuals with genetic disorders caused by nonsense mutations.

Eloxx Pharmaceuticals의 P/E 비율은 -0입니다.

Eloxx Pharmaceuticals의 P/S 비율은 0입니다.

Eloxx Pharmaceuticals에 대한 AlleAktien 품질 점수는 5/10입니다.

Eloxx Pharmaceuticals에 대한 현재 매출은 계산할 수 없습니다.

예상되는 Eloxx Pharmaceuticals 이익은 -2.27 백만 USD입니다.

Eloxx Pharmaceuticals Inc is a biotechnology company specializing in the development of therapies for rare and ultra-rare genetic diseases. The company's business model is based on identifying genetic mutations that lead to reduced or absent protein production. Eloxx utilizes its proprietary platform technology, LOXO-101, to treat faulty proteins caused by these mutations. Eloxx operates three divisions to support its strategy of developing therapies for rare diseases. These include research and development, clinical development, and commercialization. In the research and development area, Eloxx focuses on identifying genetic mutations that cause rare diseases. The company is actively researching and developing technologies to modulate genetic mutations and increase the production of missing or defective proteins in cells and tissues. Eloxx continues to expand its expertise in genomics, cell biology, and artificial intelligence in this field. The focus of Eloxx's clinical development is conducting clinical trials to evaluate the efficacy and safety of its therapies. The company conducts clinical trials in different phases to determine the appropriate dosages and administration routes for its therapies. This area also involves collaborating with regulatory authorities to obtain approval for new drugs and therapies. Commercialization is the third area in which Eloxx is involved. The company works to bring its therapies to the market to make them available to patients. Eloxx utilizes its expertise in market research, pricing, and distribution to successfully market its therapies. Eloxx has several therapies in the pipeline, including ELX-02, an mRNA therapy for the treatment of cystic fibrosis. This therapy aims to increase the production of missing or defective proteins in patients with cystic fibrosis due to a genetic mutation. The company is also working on the development of LOXO-305, a protein corrector for the treatment of immune system disorders caused by mutations in the genetic code. Eloxx Pharmaceuticals Inc is a biotechnology company specializing in the development of therapies for rare genetic diseases. The company utilizes its technologies and expertise in research and development, clinical development, and commercialization to develop therapies that aim to improve the lives of patients. Eloxx has a variety of therapies in the pipeline, including ELX-02 and LOXO-305, which offer promising treatment options for patients with rare diseases.

Eloxx Pharmaceuticals은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

Eloxx Pharmaceuticals의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Eloxx Pharmaceuticals의 ISIN은 US29014R1032입니다.

Eloxx Pharmaceuticals의 WKN은 A2JAHU입니다.

Eloxx Pharmaceuticals의 티커는 ELOX입니다.

지난 12개월 동안 Eloxx Pharmaceuticals은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Eloxx Pharmaceuticals은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

Eloxx Pharmaceuticals의 현재 배당 수익률은 입니다.

Eloxx Pharmaceuticals은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Eloxx Pharmaceuticals은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Eloxx Pharmaceuticals은 '건강' 섹터에 속합니다.

Eloxx Pharmaceuticals의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 Eloxx Pharmaceuticals는 0 USD를 배당금으로 지급했습니다.

Eloxx Pharmaceuticals의 배당금은 USD에 지급됩니다.